1 Min Read
Dec 4 (Reuters) - Astrazeneca Plc:
* PHASE IV ASCENT TRIAL MEETS PRIMARY ENDPOINTS IN COPD PATIENTS WITH CARDIOVASCULAR RISK FACTORS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.